CU2 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Revenue GrowthDouble-digit product growth and raised full-year guidance indicate expanding demand for Cerus’s blood-safety offering. Continued adoption can increase the installed customer base and recurring consumable volumes, supporting a durable revenue-growth trajectory over the next several quarters.
Recurring Consumables ModelThe consumables-based model links revenue to recurring blood-component processing rather than only equipment purchases. As customers treat ongoing volumes, repeat kit and reagent demand can improve revenue visibility and deepen customer relationships, supporting more durable commercial economics.
Product And Regulatory ExpansionRegulatory progress across platelet illumination and red-cell applications expands Cerus’s potential addressable market beyond its established products. Successful approvals and clinical results could broaden adoption, strengthen the platform’s strategic value, and create additional multi-year growth opportunities.
Bears Say
Persistent GAAP LossesCerus has improved its loss profile but remains GAAP unprofitable, showing that revenue growth has not yet translated into sustainable earnings. Continued losses can limit internally funded investment, weaken financial resilience, and leave profitability dependent on further operating leverage.
Weak Cash ConversionRecent cash generation remains too weak and inconsistent to fully support the business without external flexibility. Negative TTM free cash flow reduces funds available for research, commercialization, and debt reduction, while inventory investment could continue to pressure liquidity as growth proceeds.
Elevated LeverageLeverage above equity makes Cerus’s balance sheet less conservative while the company is still reporting losses and weak cash conversion. Debt service and refinancing requirements can constrain capital allocation, reduce tolerance for execution setbacks, and increase financial risk until profitability becomes durable.
Cerus News
CU2 FAQ
What was Cerus Corp’s price range in the past 12 months?
Currently, no data Available
What is Cerus Corp’s market cap?
Cerus Corp’s market cap is CHF409.46M.
When is Cerus Corp’s upcoming earnings report date?
Cerus Corp’s upcoming earnings report date is Oct 29, 2026 which is in 45 days.
How were Cerus Corp’s earnings last quarter?
Cerus Corp released its earnings results on Jul 30, 2026. The company reported -CHF0.008 earnings per share for the quarter, beating the consensus estimate of -CHF0.01 by CHF0.002.
Is Cerus Corp overvalued?
According to Wall Street analysts Cerus Corp’s price is currently Undervalued.
Does Cerus Corp pay dividends?
Cerus Corp does not currently pay dividends.
What is Cerus Corp’s EPS estimate?
Cerus Corp’s EPS estimate is >-0.01.
How many shares outstanding does Cerus Corp have?
Cerus Corp has 201,524,900 shares outstanding.
What happened to Cerus Corp’s price movement after its last earnings report?
Cerus Corp reported an EPS of -CHF0.008 in its last earnings report, beating expectations of -CHF0.01. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Cerus Corp?
Currently, no hedge funds are holding shares in CH:CU2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cerus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
CHF3.67 (― Upside)
CHF3.67 (― Upside)
Blogger Sentiment
Bullish
CH:CU2 Sentiment 100%
Sector Average 61%
Sector Average 61%
Insider Transactions
Sold Shares
Worth CHF43.3K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
99.20%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-3.70%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Cerus Corp
Cerus Corporation operates as a biotechnology firm dedicated to advancing and marketing the INTERCEPT Blood System. This proprietary technology significantly enhances the safety of transfusable blood components by neutralizing biological threats, thereby reducing the risk of blood-borne pathogens. The company's product line includes INTERCEPT systems specifically engineered to deactivate pathogens in donated platelets and plasma. It also offers a dedicated INTERCEPT Blood System for the inactivation of harmful agents in red blood cell components. Furthermore, Cerus markets an INTERCEPT Blood System for Cryoprecipitation, which leverages its plasma technology to produce two key pathogen-reduced blood products: a cryoprecipitated fibrinogen complex for treating and controlling bleeding, particularly massive hemorrhages stemming from fibrinogen deficiency, and pathogen-reduced, cryoprecipitate-reduced plasma. Cerus distributes these platelet and plasma systems globally through a combination of its direct sales force and an extensive network of distributors, reaching markets in North America, Europe, the Commonwealth of Independent States, the Middle East, and Latin America. Established in 1991, Cerus Corporation maintains its corporate headquarters in Concord, California.
CU2 Company Deck
CU2 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed predominantly positive momentum: double-digit product revenue growth, raised product and IFC guidance, consecutive quarters of positive adjusted EBITDA, meaningful debt refinancing benefits, regulatory progress (PMA submission and upcoming Phase 3 readout), and a clean quality audit. Counterbalancing items include a drop in gross margin (51.4% vs 55.2% prior year) driven by currency and inflationary pressures, reduced government contract revenue this quarter, modest operating cash use for inventory, and regulatory/penetration challenges in Asia-Pacific and for broader IFC adoption. On balance the positives (top-line growth, improving profitability measures, stronger balance sheet flexibility, and regulatory/clinical progress) outweigh the near-term headwinds.View all CH:CU2 earnings summariesCU2 Stock 12 Month Forecast
Average Price Target
―Tactile Systems Technology
―
Viemed Healthcare
―
Brainsway
―
Outset Medical
―
908 Devices
―